Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GKOS – Glaukos Corporation

Float Short %

4.09

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

-0.02

EPS Last/This Y

1.95

EPS This/Next Y

0.52

Price

111.73

Target Price

121.93

Analyst Recom

1.27

Performance Q

35.68

Relative Volume

1.01

Beta

0.67

Ticker: GKOS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17GKOS88.420.320.1510783
2025-11-18GKOS91.580.320.0210833
2025-11-19GKOS96.510.311.5011140
2025-11-20GKOS95.190.350.3510141
2025-11-21GKOS99.670.350.1110266
2025-11-24GKOS980.310.132164
2025-11-25GKOS104.430.300.102300
2025-11-26GKOS105.390.270.112597
2025-12-01GKOS106.10.280.622694
2025-12-02GKOS106.030.291.222727
2025-12-03GKOS107.490.322.262783
2025-12-04GKOS108.890.360.022883
2025-12-05GKOS108.50.360.262859
2025-12-08GKOS108.430.360.112905
2025-12-09GKOS106.90.360.652934
2025-12-10GKOS108.760.350.032975
2025-12-11GKOS109.270.354.402999
2025-12-12GKOS108.870.360.303018
2025-12-15GKOS111.780.360.213034
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17GKOS88.3849.778.0-0.82
2025-11-18GKOS91.6249.777.8-0.82
2025-11-19GKOS96.4949.777.8-0.82
2025-11-20GKOS95.2549.778.0-0.82
2025-11-21GKOS99.6449.777.8-0.82
2025-11-24GKOS98.0149.778.0-0.82
2025-11-25GKOS104.3549.777.7-0.82
2025-11-26GKOS105.4449.777.9-0.82
2025-12-01GKOS106.0949.778.0-0.82
2025-12-02GKOS106.0749.778.0-0.82
2025-12-03GKOS107.4649.777.9-0.82
2025-12-04GKOS108.8949.777.9-0.82
2025-12-05GKOS108.5148.778.0-0.82
2025-12-08GKOS108.4648.7- -0.82
2025-12-09GKOS106.8748.778.0-0.82
2025-12-10GKOS106.8748.777.9-0.82
2025-12-11GKOS109.2348.778.0-0.82
2025-12-12GKOS108.9048.778.0-0.82
2025-12-15GKOS111.7348.777.9-0.82
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17GKOS-0.26-1.635.33
2025-11-18GKOS-0.26-1.635.33
2025-11-19GKOS-0.26-1.635.33
2025-11-20GKOS-0.26-1.635.33
2025-11-21GKOS-1.16-1.635.33
2025-11-24GKOS-1.16-7.255.36
2025-11-25GKOS-1.02-7.255.36
2025-11-26GKOS-1.02-7.254.88
2025-12-01GKOS-1.03-7.294.88
2025-12-02GKOS-1.03-7.294.88
2025-12-03GKOS-1.03-7.294.88
2025-12-04GKOS-1.03-7.294.88
2025-12-05GKOS-1.03-7.294.88
2025-12-08GKOS-1.03-7.264.88
2025-12-09GKOS-1.03-7.264.88
2025-12-10GKOS-1.03-7.264.09
2025-12-11GKOS-1.23-7.264.09
2025-12-12GKOS-1.23-7.264.09
2025-12-15GKOS-1.23-7.244.09
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="GKOS" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.21

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-1.23

Institutional Transactions

-7.24

Beta

0.67

Average Sales Estimate Current Quarter

129

Average Sales Estimate Next Quarter

131

Fair Value

Quality Score

49

Growth Score

50

Sentiment Score

11

Actual DrawDown %

31.8

Max Drawdown 5-Year %

-64.3

Target Price

121.93

P/E

Forward P/E

PEG

P/S

13.66

P/B

8.33

P/Free Cash Flow

EPS

-1.55

Average EPS Est. Cur. Y​

-0.82

EPS Next Y. (Est.)

-0.31

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-18.65

Relative Volume

1.01

Return on Equity vs Sector %

-38.4

Return on Equity vs Industry %

-29.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

77.9
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”GKOS” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”GKOS” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Glaukos Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 995
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
stock quote shares GKOS – Glaukos Corporation Stock Price stock today
news today GKOS – Glaukos Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GKOS – Glaukos Corporation yahoo finance google finance
stock history GKOS – Glaukos Corporation invest stock market
stock prices GKOS premarket after hours
ticker GKOS fair value insiders trading